Pharmaceutical Technology
JUNE 12, 2023
A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has unanimously voted in support of Eisai and Biogen’s Leqembi and its clinical benefit in patients with early Alzheimer’s disease , raising the drug’s full approval prospects. Leqembi is the second drug developed by Biogen and Eisai for the treatment of Alzheimer’s disease.
pharmaphorum
OCTOBER 27, 2022
It’s a disappointing outcome for a programme that GSK said in 2021 could potentially generate £1 to £2 billion in peak sales because of the serious unmet need in RA patients. GSK licensed otilimab from German biotech MorphoSys in 2013 in a deal valued at up to €423 million, including around €23 million upfront. Daprodustat backed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 29, 2022
“That research led to a substantial amount of evidence suggesting that ketamine can have rapid effects on a host of measures associated with neuroplasticity,” he says. In November 2021, the Michael J. There is not a whole lot of evidence to say these effects are underlying ketamine’s therapeutic action in humans, says Kohtala.
Pharmaceutical Technology
AUGUST 17, 2022
On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. In September 2021, the same study reported a 100% seroconversion rate after a booster was given to the participants.
PM360
AUGUST 9, 2022
Indeed, in research from the 2021 PURE Report, 3 50% of the patients responding found the therapy discussion to be a highly stressful period in their treatment journey. Hospital Admissions Associated with Medication Non-Adherence: A Systematic Review of Prospective Observational Studies.” Start Patient Support Immediately.
Nixon Gwilt Law
NOVEMBER 5, 2021
On November 2, 2021, the Centers for Medicare and Medicaid Services (“CMS”) finalized the Medicare Physician Fee Schedule for Calendar Year 2022 (the “Final 2022 MPFS” or the “Final Rule”). We predict that the PHE will be extended beyond 2021, and that remote direct supervision will be permissible until at least December 31, 2022.
Pharmaceutical Technology
FEBRUARY 17, 2023
In 2021, the FDA granted Amgen’s (NASDAQ:AMGN) non-small cell lung cancer (NSCLC) drug Lumakras (sotorasib) an expedited approval, making it the first FDA-approved KRAS inhibitor. The demand came amid concerns that the drug causes a slew of side effects such as nausea, diarrhea, and liver issues.
Expert insights. Personalized for you.
52 
Let's personalize your content